Stock Traders Purchase Large Volume of Roivant Sciences Call Options (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) saw unusually large options trading on Tuesday. Stock traders purchased 11,070 call options on the stock. This is an increase of 209% compared to the average volume of 3,588 call options.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ROIV shares. Wolfe Research initiated coverage on Roivant Sciences in a report on Thursday, February 15th. They issued an "outperform" rating and a $17.00 target price on the stock. TheStreet raised Roivant Sciences from a "d" rating to a "c+" rating in a research note on Tuesday, February 13th. Deutsche Bank Aktiengesellschaft began coverage on shares of Roivant Sciences in a report on Tuesday, December 12th. They issued a "buy" rating and a $14.00 target price for the company. Bank of America upped their price objective on shares of Roivant Sciences from $11.00 to $12.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 2nd. Finally, HC Wainwright cut their target price on shares of Roivant Sciences from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Insider Transactions at Roivant Sciences

In related news, COO Eric Venker sold 96,950 shares of the company's stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the completion of the sale, the chief operating officer now owns 532,207 shares of the company's stock, valued at $5,811,700.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dagco Inc. bought a new position in Roivant Sciences during the 4th quarter worth approximately $27,000. Citigroup Inc. boosted its position in Roivant Sciences by 1,803.6% during the first quarter. Citigroup Inc. now owns 5,749 shares of the company's stock valued at $28,000 after acquiring an additional 5,447 shares during the last quarter. Royal Bank of Canada grew its holdings in Roivant Sciences by 60,550.0% during the 1st quarter. Royal Bank of Canada now owns 6,065 shares of the company's stock worth $30,000 after acquiring an additional 6,055 shares during the period. FNY Investment Advisers LLC bought a new position in shares of Roivant Sciences in the 4th quarter worth about $33,000. Finally, Headlands Technologies LLC acquired a new position in shares of Roivant Sciences in the 4th quarter valued at about $36,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 4.7 %

Shares of NASDAQ:ROIV traded up $0.49 during mid-day trading on Tuesday, reaching $10.92. 20,338,317 shares of the company's stock were exchanged, compared to its average volume of 6,992,808. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79. Roivant Sciences has a twelve month low of $6.97 and a twelve month high of $13.24. The firm has a market capitalization of $8.80 billion, a price-to-earnings ratio of 2.10 and a beta of 1.34. The business's fifty day moving average price is $10.75 and its 200-day moving average price is $10.35.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The firm had revenue of $37.14 million for the quarter, compared to the consensus estimate of $30.72 million. On average, research analysts predict that Roivant Sciences will post -1.36 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.